Experts Perspective on Indian Evidences & Clinical Applications of Vildagliptin 100 mg OD

Speciality: Diabetology

Description:

A warm welcome to all the medical professionals in this interesting session on Experts Perspective on Indian Evidences & Clinical Applications of Vildagliptin 100 mg OD
Vildagliptin, a DPP-4 inhibitor, has gained prominence in the management of type 2 diabetes mellitus (T2DM) in India, particularly with the 100 mg once-daily (OD) regimen. Indian clinical studies have highlighted its efficacy in achieving glycemic control, demonstrating significant reductions in HbA1c levels and postprandial glucose excursions. Experts emphasize the importance of these findings, considering the unique genetic, dietary, and lifestyle factors influencing diabetes management in the Indian population. The 100 mg OD dosing offers convenience and may enhance patient adherence compared to twice-daily regimens.
Indian endocrinologists and diabetologists have reported positive experiences with vildagliptin 100 mg OD in clinical practice, noting its favorable safety profile and tolerability. The incidence of hypoglycemia is notably low, making it a suitable option for elderly patients and those at risk of hypoglycemic events. Additionally, the weight-neutral effect of vildagliptin is a significant advantage, addressing concerns related to weight gain associated with other antidiabetic medications. This aspect is particularly relevant in India, where obesity and overweight are prevalent among T2DM patients.
Therefore, get an overall knowledge of experts perspective on indian evidences & clinical applications of vildagliptin 100 mg OD
 

See More Webinars @ Hidoc Webinars